- This morning, Orexigen (NASDAQ:OREX) stated that the LIGHT Study, a trial requested by the FDA to evaluate cardiovascular risk for the company’s obesity treatment candidate, … Continue Reading
Read nowInterviews - Ron Squarer, Chief Executive of Array BioPharma (NASDAQ: ARRY), sits down with PropThink.com to discuss the company’s pipeline, positioning, and commercialization strategies. Squarer says robust … Continue Reading
Read nowInterviews - In an exclusive video interview with PropThink.com, Cynosure (NASDAQ: CYNO) President and CEO Michael Davin discusses Cynosure’s expanding position in the global market as a … Continue Reading
Read nowInterviews - Mesoblast (ASX: MSB) (OTC:MEOBF) CEO Silviu Itesu speaks on his company’s adult stem cell technology, particularly mesenchymal precursor cells, and the low-cost manufacturing capabilities that … Continue Reading
Read nowInterviews - Atrium Innovations’ (TSX:ATB) (PINK:ATBIF) President and CEO Pierre Fitzgibbon discusses the company’s vertical integration, explaining that it allows for more control in tighter regulatory situations. … Continue Reading
Read now- MAKO Surgical (NASDAQ:MAKO) is down before the open this morning on after-hours release of Q2 sales figures and lowered 2012 outlook. Six-month sales of the … Continue Reading
Read now- Chelsea Therapeutics (NASDAQ:CHTP) announced today that CEO Simon Pedder will leave the company as the Board explores strategic options, with the objective of “optimizing long-term … Continue Reading
Read now